Abstract 5615: ALRN-0192519 is a potent and selective EGFR L858R mutation inhibitor that demonstrates anti-cancer activity in preclinical cancer models as monotherapy or in combination with osimertinib
Jiaqi Liang(Fudan University), Lina Gu(Cytori Therapeutics (United States)), Xipan Liu(Valerion Therapeutics (United States)), Yaoyu Chen(Wuhan Institute of Physics and Mathematics), John N. Campbell(University of Virginia), Xiang Zhai(Cytori Therapeutics (United States)), Lisha Xie(Huazhong University of Science and Technology), Tingru Zhou(Valerion Therapeutics (United States)), David B. Pirovich(Cytori Therapeutics (United States)), Xiaobin Zhang(Cytori Therapeutics (United States)), Fang Li(Jiangsu Province Hospital), Jihong Chen(Nanjing University), Yipin Lu(Cytori Therapeutics (United States)), Yezhen Zhang(Valerion Therapeutics (United States)), Tao Ji(Cytori Therapeutics (United States)), Ming Yu(University of North Carolina at Chapel Hill)
Cited by 0
Related Papers
Genetic Mechanisms of Immune Evasion in Colorectal Cancer
|Cancer Discovery|2018|558
Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer
|Genome biology|2007|343
Nano-palladium is a cellular catalyst for in vivo chemistry
|Nature Communications|2017|288
Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer
|Nature Communications|2014|269
FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma
|Clinical Cancer Research|2020|186